Ode to methotrexate

Journal of Clinical Oncology

Volumn 11, Issue 1, 1993, Pages 5-14

  Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ANIMAL; HISTORY; HISTORY OF MEDICINE; HUMAN; REVIEW;

ANIMAL; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; METHOTREXATE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027351189     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1993.11.1.5     Document Type: Article

References (100)

1. Kimura K, Wang YM (eds): Methotrexate in Cancer Therapy. Progress in Cancer Research and Therapy, vol 33. New York, NY, Raven Press, 1986
2. Wilke WAS: Methotrexate Therapy in Rheumatic Disease. New York, NY, Marcel Dekker, 1989
3. Capizzi RL, Bertino JR, Cheng YC, et al (eds): Methotrexate Update. Upper Saddle River, NJ, Postgraduate Institute of Medical Education, 1986
4. Farber S, Diamond LK, Mercer RD, et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 238:787-793, 1948
5. Huggins C, Hodges CV: Studies on prostate cancer: Effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223, 1941
6. Gilman A: The initial clinical trial of nitrogen mustard. Am J Surg 105:574-578, 1963
7. Farber S: Action of pteroylglutamic conjugates on man. Science 106:619-621, 1947
8. Heinle RW, Welch AD: Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest 27:539, 1948 (abstr)
9. Goldin A: Preclinical methodology for the selection of anticancer agents, in Busch H (ed): Methods in Cancer Research, vol IV. New York, NY, Academic Press, 1968, pp 193-254
10. Li MC, Hertz R, Spencer DB: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93:361-366, 1956
11. Hertz R, Lewis J Jr, Lipsett MB: Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Am J Obstet Gynecol 82:631-637, 1961
12. Rustin GJS, Rustin F, Dent J, et al: No increase in second tumors after cytotoxic chemotherapy for gestational neoplasms. N Engl J Med 308:1-5, 1983
13. Osborne MJ, Freeman M, Huennekens FM: Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med 97:429-431, 1958
14. Hitchings GH, Burchall JJ, Ferone R: The comparative enzymology of dihydrofolate reductase and the design of chemotherapeutic agents. Symp Soc Gen Microbiol 16:294-301, 1966
15. Acute Leukemia Group B: Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-Mercaptopurine and methotrexate. Blood 18:431-441, 1961
16. Skipper HE, Schabel FM Jr, Wilcox WAS: Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1-15, 1964
17. Skipper HE, Schable FM Jr: Quantitative and cytokinetic studies in experimental tumor systems, in Holland JF, Frei E III (eds): Cancer Medicine. Philadelphia, PA, Lea & Febiger, 1982, pp 633-662
18. Freireich EJ, Karon M, Frei E III: Quadruple combination therapy (VAMP) for acute lymphocytic leukemia. Proc Am Assoc Cancer Res 5:20, 1964 (abstr)
19. Aur RJA, Simone J, Husta HO, et al: Central nervous system therapy and combination chemotherapy in childhood lymphocytic leukemia. Blood 37:272, 1971
20. Simone JV, Aur RJA, Husta HD, et al: Three to ten years after cessation of therapy in children with leukemia. Cancer 42:839-844, 1978
21. Armstrong RD, Vera R, Snyder P, et al: Enhancement of 6-thioguanine cytotoxic activity with methotrexate. Biochem Biophy. Res Commun 109:595-601, 1982
22. Bokkerink JPM, Bakker MAH, Hulscher TW, et al: Sequence, time, and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts. Biochem Pharmacol 35:3549-3555, 1986
23. Camitta B, Leventhal S, Lauer JJ, et al: Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T non-B acute lymphocytic leukemia of childhood: A pediatric oncology group study. J Clin Oncol 7:1539-1544, 1989
24. Tan C, Trippett T, Tong W, et al: A pharmacologic guided trial of sequential methotrexate and 6 thioguanine. Proc Am Assoc Cancer Res 33:209, 1992 (abstr)
25. Matthews DP, Alden RA, Bolin JT, et al: Dihydrofolate reductase: X-ray structure of the binary csomplex with methotrexate. Science 197:452-455, 1977
26. Oefner C, D'Arcy A, Winkler FK: Crystal structure of human dihydrofolate reductase complexed with folate. Eur J Biochem 174: 377-385, 1988
27. Schweitzer BI, Dicker AP, Bertino JR: Dihydrofolate reductase as a therapeutic target. FASEB J 4:2441-2452, 1990
28. Schweitzer BI, Srimatkandandada S, Gritsman H, et al: Probing the role of two hydrophobic active site residues in the human dihydrofolate reductase by site directed mutagenesis. J Biol Chem 264: 20786-20795, 1989
29. Alt FW, Kellems RE, Bertino JR, et al: Selective multiplication of dihydrofolate reductase genes in methotrexate resistant variants of cultured murine cells. J Biol Chem 253:1357-1370, 1978
30. Fisher GA: Increased levels of folic acid reductase as a mechanism of resistance to methopterin in leukemic cells. Biochem Pharmacol 7:75-77, 1961
31. Hakala MT, Zakrewski SF, Nichol CA: Relation of folic acid reductase to ametropterin resistance in cultured mammalian cells. J Biol Chem 236:952-958, 1961
32. Friedkin M, Crawford E, Humphreys SR, et al: The association of increased dihydrofolate reductase with amenopterin resistance in mouse leukemia. Cancer Res 22:600-606, 1962
33. Biedler JL, Spengler B: Metaphase chromosome anomaly: Association with drug resistance and cell specific products. Science 191: 185-187, 1976
34. Bertino JR: The mechanism of action of the folate antagonists in man. Cancer Res 23:1286-1306, 1963
35. Bertino JR, Cashmore A, Finle M, et al: The "induction" of leukocyte and erythrocyte dihydrofolate reductase by methotrexate. II. Clinical and pharmacologic studies. Clin Pharmacol Ther 6:763-770, 1965
36. Bertino JR, Donohue DR, Simmons B: "Induction" of dihydrofolate reductase activity in leukocytes and erythrocytes of patients treated with amethopterin. J Clin Invest 42:466-475, 1963
37. Hillcoat BL, Sweet V, Bertino JR: Increase of dihydrofolate reductase activity in cultured mammalian cells after exposure to methotrexate. Proc Natl Acad Sci USA 58:1632-1637, 1967
38. Chu E, Koeller DM, Casey JL, et al: Autoregulation of human thymidylate messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 88:8977-8981, 1991
39. Dube S, Bertino JR: Gene amplification, in Dulbecco R (ed): Encyclopedia of Human Biology. San Diego, CA, Academic Press, 1991, pp 785-789
40. Chabner BA, Allegra CA, Curt GA, et al: Polyglutamylation of methotrexate: Is methotrexate a prodrug? J Clin Invest 76:907-912, 1985
41. Whitehead VM, Perrault MM, Steiner S: Tissue specific synthesis of methotrexate polyglutamates in the rat. Cancer Res 35:2985-2990, 1975
42. McGuire JJ, Bertino JR: Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 38:19-48, 1981
43. Baugh CM, Krumdieck CL, Nair MG: Polyglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 52:27-34, 1973
44. Pizzorno G, Mini E, Coronnello M, et al: Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF CEM cells alter short term, high dose treatment with this drug. Cancer Res 48:2149-2155, 1988
45. McCloskey DE, McGuire JJ, Russell CA, et al: Decrease folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181-6187, 1991
46. Cadman E, Heiner R, Davis L: Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 205:1135-1137, 1979
47. Kufe DW, Egan EM: Enhancement of 5-fluorouracil incorporation into human lymphoblastic ribonucleic acid. Biochem Pharmacol 30:129-133, 1981
48. Marsh JC, Bertino JR, Katz KH, et al: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J Clin Oncol 9:371-380, 1991
49. Romanini A, Li WW, Colofiore JR, et al: Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells. J Natl Cancer Inst 84:1033-1038, 1992
50. Goldman ID, Lichenstein WS, Oliveiro VT: Carrier mediated transport of the folic acid analog methotrexate in the L1210 leukemia cell. J Biol Chem 243:5007-5017, 1968
51. Sirotnak FM, Gontas LJ, Mines LS: Extent of requirement for folate transport by L1210 cells for growth and leukemogenesis in vivo. Cancer Res 45:4732-4734, 1985
52. Henderson GB: Transport of folate compounds into cells, in Blakley RL, Whitehead VM (eds): Folates and Pterins Nutritional, Pharmacological, and Physiological Aspects, vol 3. New York, NY, Wiley Interscience, 1986, p 207
53. Allegra CJ, Chabner BA, Drake JC, et al: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726, 1985
54. Allegra CJ, Drake JC, Jolinet J, et al: Inhibition of phosphoribosyl-aminoimidazolecarboximide transformylase by methotrexate and dihydrofolic acid polyglutamate. Proc Natl Acad Sci USA 82: 4881-4885, 1985
55. Anthony AC: The biological chemistry of folate receptors. Blood 79:2807-2820, 1992
56. Anthony AC, Utley CS, Van Horne KC, et al: Isolation and characterization of a folate receptor from human placenta. J Biol Chem 256:9684-9692, 1981
57. Andersen RGW, Kamen BA, Rothberg KG, et al: Potocytosis: Sequestration and transport of small molecules by careolae. Science 255:410-411, 1991
58. Sadasivan E, Rothenberg SP: The complete amino acid sequence of a human folate binding protein from KB cells determined from the cDNA. J Biol Chem 264:5806-5811, 1989 (correction 265: 1821, 1990)
59. Lacey SW, Sanders JM, Rothberg KG, et al: Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosylphosphatidylinositol. J Clin Invest 84:715, 1989
60. Elwood PC: Molecular cloning and characterization of the human folate binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 264:14893-14901, 1989
61. Ratnam M, Marquardt H, Dugring JL, et al: Homologous membrane folate binding proteins in human placenta: Cloning and sequence of a cDNA. Biochemistry 28:8249-8254, 1989
62. Weitman SD, Lark RH, Coney LR, et al: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52:3396-3401, 1992
63. Campbell IG, Jones TA, Foulkes WD, et al: Folate-binding protein is a marker for ovarian cancer. Cancer Res 51:5329-5338, 1991
64. Coney LR, Tomassetti A, Carayannopoulos L, et al: Cloning of tumor associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 51:6125-6132, 1991
65. Melera PW: Acquired versus intrinsic resistance to methotrexate: Diversity of the drug assistant phenotype in mammalian cells. Semin Cancer Biol 10:245-255, 1991
66. Bertino JR, Lin J, Pizzorno G, et al: The basis for intrinsic drug resistance or sensitivity to methotrexate. Adv Enzyme Reg 29: 277-285, 1989
67. Brown DH, Blaak-huis BJM, van Dongen GAMS, et al: Comparative study of the sensitivity of head and neck cell lines to methotrexate and the analog 10-ethyl,10-deaza-aminopterin (10-EdAM). Otolaryngol Head Neck Surg (in press)
68. Pizzorno G, Chang YM, McGuire JJ, et al: Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. Cancer Res 49:5275-5280, 1989
69. Li WW, Lin JT, Schweitzer BI, et al: Intrinsic resistance to methotrexate in human soft tissue sarcoma cell lines. Cancer Res 52: 3908-3913, 1992
70. Lin JT, Tong WP, Trippett TM, et al: Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leukemia Res 15:1191-1196, 1991
71. Li WW, Lin JT, Tong WP, et al: Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 52: 1434-1438, 1992
72. Bertino JR: Folate antagonists: Toward improving the therapeutic index and development of new analogs. J Clin Pharmacol 30:291-295, 1990
73. Sirotnak FM, DeGraw JI, Maccio DM, et al: New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12:13-25, 1984
74. Sirotnak FM, DeGraw JI, Schmid FA, et al: New folate analogs of the 10-deaza-aminopterin series: Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid tumor models. Cancer Chemother Pharmacol 12:26-30, 1989
75. Vandenberg KI, Pritchard E, Eisenhauer M, et al: A phase II study of weekly 10-EDAM (edatrexate) as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11:51, 1992 (abstr)
76. Shum KY, Kris MG, Gralla RJ, et al: A phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 6:446-450, 1988
77. Schornagel JH, Cappelaere P, Cognetti F, et al: A randomized phase II trial of methotrexate versus 10-ethyl-10-deaza-aminopterin in patients with advanced squamous cell carcinoma of the head and neck. 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands, 1989 (abstr 462)
78. Christman K, Casper ES, Schwartz GK, et al: Edatrexate: An active agent in malignant fibrous histiocytoma. Proc Am Soc Clin Oncol 11:413, 1992 (abstr)
79. Robert F: Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 15:22-26, 1988
80. Maloun J: Clinical response to trimetrexate as sole therapy for non-small cell cancer. Semin Oncol 15:17-21, 1988
81. Warner Lambert/Parke-Davis North American Phase II Study Group: Phase II efficacy of trimetrexate in patients with non-small-cell lung cancer. Proc Am Soc Clin Oncol 6:170, 1987 (abstr)
82. Quirt I, Eisenhauer E, Knowling M, et al: A phase II study of trimetrexate in metastatic soft tissue sarcoma. Proc Am Soc Clin Oncol 7:275, 1988 (abstr)
83. Degardin M, Domenge CH, Cappelaere P, et al: A phase II piritrexim study in recurrent and/or metastatic head and neck cancer. Proc Am Soc Clin Oncol 11:244, 1992 (abstr)
84. Feun LG, Gonzalez R, Savaraj N, et al: Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol 9:464-467, 1991
85. α-hemi-phthaloyl-L-ornithine (PT523), a potent side chain modified aminopterin analog that cannot form polyglutamates. Proc Am Assoc Cancer Res 32:325 1991 (abstr)
86. Fernandez DJ, Benino JR, Hynes JB: Biochemical and antitumor effects of 5,8-dideaza-150 pteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase. Cancer Res 43:1117-1123, 1983
87. 10-propargyl-5,8-dideazafolic acid (CB3717). Natl Cancer Inst Nanograph 5:213-218, 1987
88. Jackman AL, Taylor GA, Gibson W, et al: ICI D1694, aquinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51:5579-5586, 1992
89. Uana WHJ, Kimbell R, Jackman AL: Kinetic characteristics of ICI D1694: A quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 43:2029-2031, 1992
90. 3H ICI D1694 polyglutamate formation of L1210 cells in vitro by an HPLC ion-pairing method. Br J Cancer 6:47, 1991 (suppl 8)
91. Webber S, Shetty B, Johnston A, et al: In vitro properties and antitumor activity of AG-331, a novel lipophilic thymicylate synthase inhibitor. Proc Am Assoc Cancer Res 33:413, 1992 (abstr)
92. Beardsley GP, Moroson BA, Taylor EC, et al: A new folate antimetabolite, 5-10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333, 1989
93. Wang X, Freisheim JH, Gentry LE, et al: Differences in stero specificity of membrane folate receptor isoforms for reduced folates Proc Am Assoc Cancer Res 33:414, 1992 (abstr)
94. Young CW, Currie VE, Muindi JF, et al: Phase I study of lometrexol: Improved clinical tolerance with oral folic acid. NCI-EORTC Symposium, Amsterdam, the Netherlands, 1992 (abstr)
95. Miller AD: Progress toward human gene therapy. Blood 76: 271-278, 1990
96. Li M, Hantzopoulos PA, Banerjee D, et al: Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther 3:381-390, 1992
97. Zhao SC, Banerjee D, Li MX, et al: Efficient transfer in a persistent expression of mutant DHFR gene in normal mouse hematopoietic cells. Proc Am Assoc Cancer Res 33:494, 1992
98. Cory CA, DeSilva AD, Holland CA, et al: Serial transplantation in methotrexate resistant bone marrow: Protection of murine recipients from drug toxicity by progeny of transduced stem cells. Blood 75:337-343, 1990
99. Sorrentino BP, Brandt SJ, Bodine D, et al: Selection of drug resistant gene marrow cells in vivo after retroviral transfer of human MDRI, Science 257:99-103, 1992
100. Hitchings GH: Salmon, butterflies, and cancer chemotherapy, in Pharmacologic Basis of Cancer Chemotherapy. MD Anderson Hospital Tumor Institute at Houston. Baltimore, MD, Williams & Willkins, 1975, pp 25-43